Filing Analysis
Annovis Bio, Inc. filed an 8-K to report its quarterly earnings results for the period ending June 30, 2026. The filing serves as a formal announcement of the company's financial performance and operational updates via a press release.
📋 Key Facts
- Reporting date: August 14, 2026
- Period covered: Quarter ended June 30, 2026
- The filing includes an earnings press release as Exhibit 99.1
- Signed by Maria Maccecchini, President and CEO
Annovis Bio, Inc. announced the successful completion of full enrollment for its pivotal Phase 3 clinical trial evaluating buntanetap in patients with early Alzheimer's Disease (AD). The trial reached its target enrollment of 850 patients across 83 sites.
📋 Key Facts
- Full enrollment achieved for Phase 3 trial (NCT06709014) on July 7, 2026.
- Trial evaluates buntanetap in patients with early AD.
- Total enrollment reached 850 patients.
- Patients were confirmed to have pTau217-confirmed AD pathology.
- Enrollment occurred across 83 clinical sites in the US.
Annovis Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. All five submitted proposals, including the election of directors and the ratification of auditors, were approved.
📋 Key Facts
- Annual Meeting held virtually on June 17, 2026.
- Quorum represented by 21,705,113 shares (62.65% of outstanding common stock).
- Five directors were elected: Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White.
- Ernst & Young LLP was ratified as the independent auditor.
- The 2019 Equity Incentive Plan was amended to increase total issuable shares from 4,000,000 to 5,500,000 and annual award limits from 400,000 to 600,000.
- Stockholders approved a biennial (every two years) frequency for advisory votes on executive compensation.
Annovis Bio, Inc. entered into an underwriting agreement with Canaccord Genuity LLC for a public offering to raise approximately $15 million in gross proceeds. The offering consists of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 shares at a combined price of $1.90.
🚩 Red Flags
- High dilution risk from nearly 90% warrant coverage (7,105,500 warrants accompanying 7,895,000 shares).
- Warrants are immediately exercisable, which may create immediate downward pressure on the stock price.
📋 Key Facts
- Underwriting Agreement dated May 20, 2026, with Canaccord Genuity LLC.
- Offering of 7,895,000 shares of common stock and warrants to purchase up to 7,105,500 shares.
- Combined offering price of $1.90 per share and nine-tenths of a warrant.
- Warrants are immediately exercisable at $2.25 per share and expire in six years.
- Expected gross proceeds of approximately $15 million before offering expenses.
- Net proceeds intended for clinical development of lead compound Buntanetap for Alzheimer's and Parkinson's diseases.
Annovis Bio, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the Form 8-K.
📋 Key Facts
- The company reported earnings for the fiscal quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued and dated May 15, 2026.
- The filing includes Exhibit 99.1, which contains the full text of the earnings announcement.
Annovis Bio, Inc. entered into an underwriting agreement for a $10 million registered direct offering of common stock and warrants. The proceeds are primarily intended to fund the Phase 3 clinical development of Buntanetap for Alzheimer's disease.
🚩 Red Flags
- Significant dilution potential from the issuance of 5.26 million shares plus an equal number of warrants.
- The offering price of $1.90 may represent a discount to recent trading prices (typical in such offerings).
📋 Key Facts
- Agreement with Canaccord Genuity LLC to issue 5,263,156 shares of common stock.
- Issuance of 5,263,156 accompanying warrants with an exercise price of $2.50.
- Combined offering price of $1.90 per share and warrant unit.
- Expected gross proceeds of approximately $10 million before expenses.
- Warrants are exercisable starting six months after issuance and expire in 5.5 years.
- Proceeds earmarked for Phase 3 study of Buntanetap and general working capital.
Mark Guerin has departed as Chief Financial Officer of Annovis Bio, Inc. effective March 23, 2026. The company's CEO, Maria Maccecchini, will serve as the Acting CFO until a permanent replacement is identified.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer.
- CEO assuming dual roles (CEO and Acting CFO), which can reduce financial oversight and internal control checks.
📋 Key Facts
- Mark Guerin's employment as CFO ended on March 23, 2026.
- CEO Maria Maccecchini is expected to be appointed as Acting CFO.
- The company states the departure was not due to any disagreement regarding operations, policies, or practices.
- The filing was made under Item 5.02 of Form 8-K.
Annovis Bio, Inc. reported its financial results for the fiscal year ended December 31, 2025, via a press release furnished with the SEC.
🚩 Red Flags
- Clerical inconsistency: The exhibit description lists the press release date as March 16, 2025, while the filing and report date is March 16, 2026.
📋 Key Facts
- Earnings reported for the fiscal year ended December 31, 2025.
- Filing includes Item 2.02 for Results of Operations and Financial Condition.
- Press release is furnished as Exhibit 99.
- The filing is dated March 16, 2026.
Annovis Bio, Inc. filed an 8-K to furnish a press release dated February 12, 2026, under Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial or operational data beyond the announcement of the press release.
📋 Key Facts
- Filing date: February 12, 2026
- The company is an emerging growth company.
- The filing serves to furnish a press release as Exhibit 99.1 under Item 7.01.
Annovis Bio, Inc. filed an 8-K to announce a webinar held on January 28, 2026, and provided a presentation as an exhibit.
📋 Key Facts
- The company conducted a webinar on January 28, 2026.
- A presentation related to the webinar was furnished as Exhibit 99.1.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
Annovis Bio, Inc. filed an 8-K to report its quarterly earnings results for the period ended September 30, 2025. The filing serves as a formal announcement of the company's financial performance and operational updates via a press release.
📋 Key Facts
- Reported earnings for the quarter and nine months ended September 30, 2025.
- The report was issued on November 12, 2025.
- The company is classified as an emerging growth company.
Annovis Bio, Inc. entered into a registered direct offering to issue 1,670,732 shares of common stock at $2.05 per share, raising approximately $3.425 million in gross proceeds. The offering includes participation from two members of the Board of Directors and is intended to fund Phase 3 clinical development of Buntanetap for Alzheimer’s disease.
🚩 Red Flags
- Related-party transactions: Significant portion of the offering (1,073,171 shares) is being purchased by two members of the Board of Directors.
- Dilution: Issuance of 1.67M shares at $2.05 per share represents a significant capital raise for a micro-cap company.
📋 Key Facts
- Total shares to be issued: 1,670,732 common shares.
- Offering price: $2.05 per share.
- Expected gross proceeds: ~$3.425 million (before expenses).
- Two Board members are participating in the offering via Subscription Agreements for 1,073,171 shares.
- Placement Agent fee: 7.0% of aggregate gross proceeds (excluding director/officer sales) plus expense reimbursement.
- Warrants issued to Placement Agent: Up to 83,537 shares at an exercise price of $2.5625 per share.
- Use of proceeds: Clinical development of Buntanetap (Phase 3 Alzheimer's study), working capital, and general corporate purposes.
Annovis Bio, Inc. entered into a securities purchase agreement for a registered direct offering of 3,150,000 shares and 850,000 pre-funded warrants at $1.50 per share. The company intends to use the approximately $6.0 million in gross proceeds to fund Phase 3 clinical development of Buntanetap for Alzheimer’s disease.
🚩 Red Flags
- Dilutive offering: Issuance of significant new shares and warrants will dilute existing shareholders.
- Pre-funded warrants: The use of pre-funded warrants is often used when investors want to avoid certain ownership thresholds or regulatory complexities, but it still represents future dilution.
📋 Key Facts
- Offering size: 3,150,000 common shares and 850,000 pre-funded warrants.
- Pricing: $1.50 per share; $1.4999 per pre-funded warrant.
- Expected gross proceeds: Approximately $6.0 million (before expenses).
- Use of proceeds: Clinical development of Buntanetap (Phase 3 Alzheimer's study) and working capital.
- Placement Agent Warrants: 200,000 shares at an exercise price of $2.20 per share with a 5-year term.
- Lock-up period: Directors and officers are subject to a 45-day lock-up following the closing date.
Annovis Bio, Inc. announced the appointment of Mark Guerin as the new Chief Financial Officer, effective September 25, 2025.
📋 Key Facts
- Mark Guerin appointed as CFO effective September 25, 2025.
- Guerin previously served as CFO of Onconova Therapeutics (now Traws Pharma, Inc.) from 2016 to February 2025.
- Compensation package includes a $450,000 annual base salary and a 40% target bonus.
- Equity component: Stock options to purchase 200,000 shares of common stock.
- Severance terms include six months of pay.
Annovis Bio, Inc. announced the resignation of Andrew Walsh as Vice President of Finance and Principal Financial Officer, effective August 22, 2025. To ensure continuity, CEO Maria Maccecchini has been appointed to serve as Acting Chief Financial Officer while a permanent replacement is sought.
🚩 Red Flags
- Sudden departure of the Principal Financial Officer (PFO) in a micro-cap biotech setting can create temporary administrative/reporting gaps.
- CEO taking on dual roles (Acting CFO) increases management bandwidth pressure during critical clinical or regulatory phases common to this sector.
📋 Key Facts
- Andrew Walsh resigned from his role as VP of Finance/Principal Financial Officer on August 11, 2025.
- The resignation is effective August 22, 2025.
- The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
- CEO Maria Maccecchini has been appointed Acting CFO as of August 15, 2025.
- The company is actively searching for a new permanent CFO.
Annovis Bio, Inc. filed an 8-K to furnish its second quarter 2025 financial results (ended June 30, 2025) and provide a corporate update via press release.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Annovis Bio, Inc. held its 2025 Annual Meeting of Stockholders on June 17, 2025. All proposals, including the election of five directors and the ratification of Ernst & Young LLP as independent auditors, were approved by stockholders.
📋 Key Facts
- Annual Meeting held virtually on June 17, 2025.
- Quorum represented 11,588,981 shares, or 59.47% of common stock outstanding as of April 28, 2025.
- Five nominees elected to the Board: Maria Maccecchini, Michael Hoffman, Claudine Bruck, Reid McCarthy, and Mark White.
- Stockholders ratified the appointment of Ernst & Young LLP as independent auditors.
Annovis Bio, Inc. announced that the New York Stock Exchange (NYSE) has accepted its previously submitted listing compliance plan. This follows a period of non-compliance regarding NYSE listing requirements.
🚩 Red Flags
- Delisting risk: The necessity of a 'compliance plan' indicates the company was in violation of NYSE listing standards (likely minimum bid price or market cap requirements).
- Regulatory scrutiny regarding continued exchange presence.
📋 Key Facts
- The company issued a press release on June 19, 2025, regarding its NYSE listing status.
- The NYSE has officially accepted the Company's previously submitted listing compliance plan.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for liability purposes under Section 18.
Annovis Bio, Inc. announced the appointment of Andrew Walsh as Principal Financial Officer, effective May 9, 2025. The company also issued a press release regarding its Q1 2025 financial results and corporate update.
📋 Key Facts
- Andrew Walsh appointed as Principal Financial Officer on May 9, 2025.
- Mr. Walsh previously served as VP of Finance since December 2023.
- Compensation for new PFO includes a $264,000 annual base salary and a 25% target cash bonus.
- Company released Q1 2025 financial results on May 13, 2025.
Annovis Bio, Inc. received a notice from the NYSE regarding non-compliance with continued listing standards due to insufficient market capitalization and stockholders' equity. Additionally, the company announced the departure of its Interim CFO.
🚩 Red Flags
- Delisting notice from NYSE due to low market cap and equity
- Extremely low stockholders' equity ($9.3M) relative to the $50M requirement
- Departure of Interim CFO (though stated as mutual agreement without dispute)
- Multiple 8-K items in a single filing (Delisting + Officer Departure)
📋 Key Facts
- NYSE Notice Date: March 26, 2025
- Reason for Non-Compliance: Average market cap < $50M ($37.9M as of March 25, 2025) and stockholders' equity < $50M ($9.3M as of Dec 31, 2024).
- Cure Period: The company has 18 months to regain compliance via a submitted plan.
- Ticker Status: Trading will continue on NYSE with an added '.BC' designation (Below Criteria) during the cure period.
- Officer Change: Interim CFO William Fricker is departing effective March 27, 2025; Maria Maccecchini remains as interim principal financial officer.
Annovis Bio, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2024, alongside a corporate update.
📋 Key Facts
- Report date: March 21, 2025
- Reporting period: Q4 and Fiscal Year ended December 31, 2024
- The filing includes results of operations and financial condition updates via Exhibit 99.1
- Company is classified as an emerging growth company
Annovis Bio, Inc. announced that the first patients have been enrolled in its pivotal Phase 3 clinical study for the treatment of early Alzheimer's disease.
📋 Key Facts
- Date of event: February 5, 2025
- Company has commenced enrollment for a pivotal Phase 3 study for early Alzheimer’s disease
- The announcement is made via Item 7.01 (Regulation FD Disclosure)
Annovis Bio, Inc. entered into an underwriting agreement for a public offering of 5,250,000 units at $4.00 per unit, totaling $21 million in gross proceeds. The offering consists of one share of common stock and one warrant per unit.
🚩 Red Flags
- Dilution risk: Issuance of 5.25 million new shares plus 5.25 million warrants will significantly dilute existing shareholders.
📋 Key Facts
- Offering size: 5,250,000 units (one share + one warrant per unit).
- Pricing: $4.00 per unit.
- Aggregate gross proceeds: $21,000,000 (before fees and expenses).
- Warrant terms: Exercise price of $5.00 per share; immediately exercisable; 5-year expiration.
- Use of proceeds: Continued clinical development of Buntanetap in Phase 3 Alzheimer’s study, working capital, and general corporate purposes.
- Underwriter: ThinkEquity LLC.
Annovis Bio, Inc. filed an 8-K to announce a live webcast investor presentation scheduled for December 11, 2024. The filing includes an updated investor deck as Exhibit 99.1.
📋 Key Facts
- The company is conducting a live webcast investor presentation on December 11, 2024.
- An updated investor deck has been furnished as Exhibit 99.1.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
Annovis Bio, Inc. entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. to establish an at-the-market (ATM) offering program. The company intends to sell up to $50,000,000 in common stock through this program.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $50M ATM offering capacity.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing operational burn rates, which can signal a need for immediate liquidity.
📋 Key Facts
- Entered into a Distribution Agreement with Oppenheimer & Co. Inc. on December 11, 2024.
- The offering is an 'at-the-market' (ATM) program for up to $50,000,000 in common stock.
- Oppenheimer will receive a commission of 3.0% of the gross sales proceeds.
- Shares will be issued pursuant to a shelf Registration Statement on Form S-3 that became effective on February 12, 2024.
- The company is not obligated to sell any specific amount and may suspend or terminate the agreement at its discretion.
Annovis Bio, Inc. announced the appointment of William Fricker as interim Chief Financial Officer effective December 4, 2024. Mr. Fricker is serving on a contract basis rather than through a standard employment agreement.
🚩 Red Flags
- Appointment of an 'interim' officer often suggests unexpected turnover or a gap in permanent leadership.
- The use of a contract basis rather than a standard employment agreement can indicate a temporary fix for financial oversight.
📋 Key Facts
- William Fricker appointed as interim CFO on December 4, 2024.
- Mr. Fricker is serving on a contract basis; no formal employment agreement was entered into.
- Fricker has prior experience as CFO for NRX Pharmaceuticals and CAO for Immunomedics (acquired by Gilead).
- No related-party transactions involving the new officer were disclosed under Item 404(a).
Annovis Bio, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024, along with a corporate update via press release.
📋 Key Facts
- The filing is related to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were announced on November 11, 2024.
- The reporting period covers the quarter ended September 30, 2024.
- The company is classified as an emerging growth company.
Annovis Bio, Inc. issued an 8-K to announce the results of its End-of-Phase 2 meeting with the FDA held on October 10, 2024. The filing serves as a formal vehicle to distribute a press release containing clinical development updates.
📋 Key Facts
- The company held an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024.
- The filing is used to provide an overview of the FDA meeting via a press release (Exhibit 99.1).
- The company is classified as an 'emerging growth company'.
Annovis Bio, Inc. announced the filing of three new patents regarding combination therapies for its lead compound, Buntanetap, specifically when used in conjunction with Trulicity (dulaglutide) and Viagra (sildenafil).
📋 Key Facts
- Filed on September 30, 2024.
- Three new patents filed for combination therapies involving lead compound Buntanetap.
- Combination therapies involve Buntanetap with Trulicity (dulaglutide) and Viagra (sildenafil).
Annovis Bio, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024, and provided a general corporate update via press release.
📋 Key Facts
- Report date: August 15, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Annovis Bio, Inc. issued a press release regarding preclinical data for its lead compound, Buntanetap, specifically looking at the effects of combining it with a GLP-1 agonist in Alzheimer's disease mouse models.
📋 Key Facts
- Announcement date: August 6, 2024
- Subject matter: Preclinical data for lead compound Buntanetap
- Study parameters: Combination therapy with a glucagon-like peptide 1 (GLP-1) agonist
- Model used: Mouse model of Alzheimer’s disease
Annovis Bio, Inc. announced that the FDA has approved a transition to a new crystal form of its drug candidate, Buntanetap, for use in future clinical trials.
📋 Key Facts
- FDA approval granted to transition to a new crystal form of Buntanetap.
- The change is intended for use in upcoming/future clinical trials.
- Filing date: July 16, 2024.
Annovis Bio, Inc. announced the exercise of 0.8 million warrants previously issued on November 1, 2023. The exercise resulted in $7.0 million in gross proceeds and the issuance of approximately 0.8 million shares of common stock.
🚩 Red Flags
- Dilution: The issuance of 0.8 million new shares increases the total share count, potentially diluting existing shareholders.
📋 Key Facts
- Date of exercise: Between July 8, 2024, and July 9, 2024.
- Number of warrants exercised: 0.8 million.
- Exercise price per share: $9.00.
- Gross proceeds generated: $7.0 million.
- Shares issued: Approximately 0.8 million shares of common stock.
Annovis Bio, Inc. issued an 8-K to announce the release of new data from its Phase III clinical study for Parkinson's disease. The company scheduled a webcast for July 2, 2024, to discuss these findings in detail.
🚩 Red Flags
- Clinical trial data releases in micro-cap biotech are high-volatility events; outcome directionality is not specified in this cover filing, posing binary risk to investors.
📋 Key Facts
- Company announced new data from its Phase III Parkinson’s study on July 2, 2024.
- A webcast was scheduled for 4:30 PM ET on July 2, 2024, to discuss the findings.
- The filing is a Regulation FD disclosure (Item 7.01) regarding clinical trial results.
Annovis Bio, Inc. held its 2024 Annual Meeting of Stockholders on June 12, 2024, where all submitted proposals were approved by shareholders.
📋 Key Facts
- The Annual Meeting was held virtually on June 12, 2024.
- A total of 7,278,396 shares (66.10% of outstanding common stock as of April 18, 2024) were represented.
- Five nominees—Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White—were elected to the Board of Directors.
- Shareholders approved an amendment to the 2019 Equity Incentive Plan to add 1,000,000 shares to the share reserve.
- Shareholders ratified the appointment of Ernst & Young LLP as independent auditors for fiscal year 2024.
Annovis Bio, Inc. issued a press release regarding positive clinical data for its lead drug candidate, Buntanetap. The results showed statistically significant efficacy and safety in both carriers and non-carriers of the APOE4 genetic cause of Alzheimer's disease.
📋 Key Facts
- Lead drug candidate: Buntanetap
- Target condition: Alzheimer's disease (AD)
- Clinical finding: Statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4)
- Event date: June 11, 2024
- The company held a webcast to discuss findings and future development plans.
Annovis Bio, Inc. filed an 8-K to announce a press release regarding an upcoming investor webcast scheduled for June 11, 2024.
📋 Key Facts
- Investor webcast is scheduled for June 11, 2024, at 4:30pm ET.
- The filing serves to furnish a press release (Exhibit 99.1) as per Item 7.01 Regulation FD Disclosure.
Annovis Bio, Inc. filed an 8-K to furnish a press release issued on May 21, 2024. The filing serves as a placeholder for regulatory compliance regarding the dissemination of material information via Exhibit 99.1.
📋 Key Facts
- The company is an emerging growth company.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- A press release dated May 21, 2024, is attached as Exhibit 99.1.
Annovis Bio, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024, and provided a corporate update via press release.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes financial results and a corporate update furnished as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Annovis Bio, Inc. filed an 8-K to furnish a press release issued on May 9, 2024. The filing serves as a placeholder for regulatory compliance regarding the disclosure of material information via Exhibit 99.1.
📋 Key Facts
- Filing date: May 9, 2024
- The company is an emerging growth company.
- The primary purpose of this filing is to furnish a press release dated May 9, 2024 (Exhibit 99.1).
- The registrant's CEO is Maria Maccecchini.
Annovis Bio, Inc. filed an 8-K to furnish a press release issued on May 6, 2024. The filing does not contain specific financial data or material event details within the text provided.
📋 Key Facts
- The filing was submitted on May 6, 2024.
- The company is an emerging growth company.
- The primary purpose of the filing is to furnish a press release (Exhibit 99.1) pursuant to Item 7.01.
Annovis Bio, Inc. has closed a transaction related to a Common Stock Purchase Agreement with an equity line investor, following an initial announcement on April 26, 2024.
🚩 Red Flags
- Use of an equity line investor (often associated with dilutive financing for micro-cap companies to manage liquidity).
📋 Key Facts
- The company entered into a Common Stock Purchase Agreement with an equity line investor on April 25, 2024.
- The transaction contemplated by the agreement closed on May 2, 2024.
- Legal opinion from Loeb & Loeb LLP was filed in connection with the issuance of securities.
Annovis Bio, Inc. announced the departure of its CFO and Principal Financial Officer, Henry Hagopian, effective April 30, 2024. The company has appointed CEO Maria Maccecchini as interim PFO to ensure continuity.
🚩 Red Flags
- Sudden departure of a key financial officer (CFO) in a micro-cap biotech environment.
- CEO assuming the role of interim PFO indicates potential lack of immediate succession planning or resource constraints.
📋 Key Facts
- Henry Hagopian resigned as CFO and Principal Financial Officer effective April 30, 2024.
- The resignation was stated to be not due to any disagreement regarding accounting principles or financial disclosures.
- Maria Maccecchini (CEO) has been appointed interim Principal Financial Officer effective May 1, 2024.
- Separation package includes 2 months of base salary and 2 months of medical/dental premium reimbursement.
- The agreement includes the immediate vesting of 10,000 stock options and an extension of exercise periods for existing options until December 31, 2024.
Annovis Bio, Inc. entered into a Common Stock Purchase Agreement with Keystone (ELOC Purchaser) for an equity line of credit (ELOC). The agreement allows the company to sell up to 2,051,428 shares at market-based prices to raise working capital.
🚩 Red Flags
- Equity Line of Credit (ELOC) structure often indicates a need for immediate liquidity to fund operations.
- Potential for significant shareholder dilution through the issuance of up to 2.05 million shares.
- The agreement includes standard termination clauses related to bankruptcy proceedings.
📋 Key Facts
- Entered into a Common Stock Purchase Agreement on April 25, 2024.
- The ELOC Purchaser has committed to purchase up to 2,051,428 shares of common stock.
- Includes $375,000 in 'commitment shares' to be delivered in three tranches (initial, 90-day, and 180-day).
- The company will control the timing and amount of sales; there is no obligation for the purchaser to buy.
- Sale price per share is based on market price at the time of sale.
- Proceeds are intended for working capital and general corporate purposes.
Annovis Bio, Inc. filed an 8-K to furnish its quarterly earnings press release for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of financial results and a corporate update.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Report date: April 2, 2024.
- The filing includes an earnings press release as Exhibit 99.1.
- Company is classified as an 'Emerging Growth Company'.
Annovis Bio, Inc. closed a private placement of common stock on March 22, 2024, raising $3 million in gross proceeds from an institutional investor.
🚩 Red Flags
- Dilutive event: Issuance of new common shares increases the total share count, potentially diluting existing shareholders.
📋 Key Facts
- The company issued and sold 316,455 shares of Common Stock.
- The offering price was set at $9.48 per share.
- Gross proceeds from the transaction totaled $3,000,000.
- The sale was conducted under a previously declared effective shelf registration statement (Form S-3) dated February 12, 2024.
- The offering was closed on March 22, 2024.
Annovis Bio, Inc. entered into a Securities Purchase Agreement on March 21, 2024, to sell 316,455 shares of common stock at $9.48 per share to an institutional investor for total gross proceeds of $3,000,000.
🚩 Red Flags
- The offering size ($3M) is relatively small for a biotech company, suggesting a need for immediate working capital.
- Restrictive covenants (no other equity issuances/registration filings for 30 days) limit management's flexibility in the immediate aftermath of the closing.
📋 Key Facts
- Total aggregate gross proceeds: $3,000,000
- Number of shares to be issued: 316,455 common shares
- Price per share: $9.48
- The offering is being conducted via a currently effective S-3 shelf registration statement (No. 333-276814).
- Closing is contingent upon the listing of the Common Shares on the NYSE.
- Includes a 30-day restrictive covenant preventing additional equity issuance, warrant modification, or new registration statements post-closing.
Annovis Bio, Inc. filed an 8-K to furnish a press release issued on March 20, 2024, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a placeholder for a press release dated March 20, 2024 (Exhibit 99.1).
- The company is an emerging growth company.
- The report was signed by Maria Maccecchini, President and CEO.
Annovis Bio, Inc. successfully closed a private placement of common stock on March 19, 2024. The company raised $1,025,000 in gross proceeds through the sale of 114,911 shares to an institutional investor.
🚩 Red Flags
- Small capital raise ($1M+) may indicate ongoing need for liquidity to fund operations/clinical trials typical of micro-cap biotech firms.
📋 Key Facts
- Closing date: March 19, 2024
- Total gross proceeds: $1,025,000
- Number of shares issued: 114,911 common shares
- Offering price per share: $8.92
- The offering was conducted under a previously declared effective shelf registration statement (Form S-3) dated February 12, 2024.
Annovis Bio, Inc. entered into a Securities Purchase Agreement to issue 114,911 shares of common stock at $8.92 per share to an institutional investor for total gross proceeds of $1,025,000.
🚩 Red Flags
- Small capital raise ($1.025M) relative to typical biotech R&D needs, suggesting potential liquidity constraints.
- Restrictive covenant: The company is prohibited from issuing additional equity or filing new registration statements for 30 days post-closing.
📋 Key Facts
- Date of agreement: March 15, 2024
- Total aggregate gross proceeds: $1,025,000
- Number of shares to be issued: 114,911 common shares
- Price per share: $8.92
- Issuance method: Pursuant to an effective S-3 shelf registration statement (No. 333-276814)
- Closing condition includes the listing of the Common Shares on the NYSE